Cagrilintide/GLP-1 Blend 5+5mg

The cagrilintide and semaglutide combination is a next-generation investigational peptide blend developed to maximize weight loss and metabolic control. Cagrilintide is a long-acting amylin analogue with dual amylin and calcitonin receptor activity, whereas semaglutide is a once-weekly GLP-1 receptor agonist with robust anti-hyperglycemic and appetite-suppressing effects. Preclinical and clinical studies demonstrate that co-administration of these peptides achieves superior reductions in bodyweight, appetite, and fasting glucose than either agent alone—achieving up to a 17% reduction in bodyweight in non-diabetic individuals and a 15.6% reduction in patients with type 2 diabetes over 20–32 weeks. Notably, this combination exerts additive or synergistic actions by targeting distinct neuroendocrine pathways: cagrilintide modulates homeostatic and hedonic food regulation centers in the hindbrain and hypothalamus, while semaglutide engages central and peripheral GLP-1 pathways to reduce calorie intake and improve glycemic regulation. The blend is well tolerated, with gastrointestinal effects being the most frequent adverse events and no evidence of clinically significant safety concerns or neutralizing antibody responses to cagrilintide during short-term exposure^1-3.